Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Sir Demis Hassabis said it feels like a recognition that AI is mature enough now to help with scientific discovery. Read more at straitstimes.com. Read more at straitstimes.com.

Sam Altman and Demis Hassabis, the CEOs of OpenAI and Google DeepMind, respectively, have both made recent claims that powerful, world-altering AI systems are just around the corner.

In a $30 million mansion perched on a cliff overlooking the Golden Gate Bridge, a group of AI researchers, philosophers, and technologists gathered to discuss the end of humanity. The Sunday ...

We and our 911 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under ...

Speaking at the SXSW London festival, Demis Hassabis, CEO of Google DeepMind, revealed that his team is developing a “next-generation email” system powered by AI. The goal? To liberate people ...

Demis Hassabis, DeepMind's founder and chief executive, has taken the same roles at Isomorphic Labs on an interim basis, saying in a blog post that the new company will "reimagine the entire drug ...

The start-up – which has emerged from Google parent Alphabet's DeepMind project and is led by DeepMind founder Sir Demis Hassabis – said the financing was led by Thrive Capital, with ...

Demis Hassabis, Andrej Karpathy, and Elon Musk discussed using the game Diplomacy to test AI. One AI researcher took them up on it and built a new game called "AI Diplomacy." He found that OpenAI ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

NB.1.8.1 has mutations that could increase the virus’s transmissibility and decrease the efficacy of certain neutralizing antibodies against it.

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...